The agency has also affirmed the company's short term rating at 'CARE A1+'. CARE Ratings stated that the ratings assigned to bank facilities of Divi's Laboratories continue to derive strength from the extensive experience of promoters and management team in the pharmaceutical industry, the company's established track record in Contract Research and Manufacturing Services (CRAMS) segment with reputed clientele, its strong research and development (R&D) capabilities and favourable industry outlook. Ratings factor in strong credit metrics characterised by sound capital structure, robust debt coverage indicators, and healthy liquidity maintained by the company. However, ratings are tempered by product and customer concentration risk despite reduced in FY24 as against FY23, working capital intensive operations, though funded entirely through internal accruals, exposure to the regulatory risk and forex fluctuation risk considering majority of the revenue being derived from exports. Stabilisation of total operating income (TOI) and attenuation in profitability margins in FY24 is primarily attributed to change in product mix, pricing pressure in generics segment, rise in raw material prices and freight costs. CARE Ratings expects improvement in TOI and margins in FY25 considering launch of new products, broadening of customer base, ease of raw material prices, improving demand, addition of capacity with operationalisation of Kakinada plant in second half of FY25, and increase in overall capacity utilisation. Divi's Laboratories is a pharmaceutical company engaged in generic API, custom synthesis, and nutraceuticals. The company is catering to therapeutic segments such as cardiovascular, anti-inflammatory, anti-cancer, central nervous system drugs among others. Divi's currently has seven manufacturing units (one in Kakinada under construction) and three R&D centres spread across Telangana and Andhra Pradesh. The scrip rose 0.42% to currently trade at Rs 5518.80 on the BSE. Powered by Capital Market - Live

Divis Laboratories has received reaffirmation in credit ratings for bank facilities aggregating Rs 515 crore at CARE AA+; Stable/ CARE A1+ from CARE Ratings. Powered by Capital Market - Live

Divis Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 5161.25, up 0.46% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.01% on the day, quoting at 24855.65. The Sensex is at 81293.96, up 0.14%. Divis Laboratories Ltd has risen around 5.53% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has risen around 3.38% in last one month and is currently quoting at 23043.4, down 0.37% on the day. The volume in the stock stood at 2.18 lakh shares today, compared to the daily average of 4.9 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 5176, up 0.74% on the day. Divis Laboratories Ltd is up 38.14% in last one year as compared to a 24.3% spurt in NIFTY and a 49.95% spurt in the Nifty Pharma index.The PE of the stock is 82.16 based on TTM earnings ending June 24.Powered by Capital Market - Live

Divis Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5151.7, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Divis Laboratories Ltd has risen around 6.71% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has risen around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 1.87 lakh shares today, compared to the daily average of 4.92 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 5159.45, up 0.89% on the day. Divis Laboratories Ltd is up 38.94% in last one year as compared to a 28.41% spurt in NIFTY and a 52.01% spurt in the Nifty Pharma index.The PE of the stock is 81.45 based on TTM earnings ending June 24.Powered by Capital Market - Live

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 4884.75, up 3.42% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.12% on the day, quoting at 24728.5. The Sensex is at 80764.15, down 0.05%. Divis Laboratories Ltd has gained around 7.72% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 9.29% in last one month and is currently quoting at 22374.25, up 0.83% on the day. The volume in the stock stood at 10.29 lakh shares today, compared to the daily average of 6.01 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 4881, up 3.44% on the day. Divis Laboratories Ltd is up 33.71% in last one year as compared to a 27.49% jump in NIFTY and a 47.43% jump in the Nifty Pharma index.The PE of the stock is 75.46 based on TTM earnings ending June 24.Powered by Capital Market - Live